ARK Genomic Revolution ETF vs Citius Pharmaceuticals Inc — how do they compare? ARK Genomic Revolution ETF trades at $44.5, while Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | CTXR | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $44.55 | $1.82 |
52-Week Low | $24.02 | $0.48 |
Market Cap | — | $20.01M |
Enterprise Value | — | $16.23M |
Trailing returns across standard periods
Latest headlines on both assets
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →